{
    "nctId": "NCT01444456",
    "briefTitle": "Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia",
    "officialTitle": "Electronic Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia: An International Prospective Observational Study (eAQUA)",
    "overallStatus": "COMPLETED",
    "conditions": "Anemia, Breast Cancer, Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Solid Tumors, Bladder Cancer, Endometrial Cancer, Renal Cancer, Pancreatic Cancer, Esophageal Cancer, Gastric Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 1262,
    "primaryOutcomeMeasure": "Percentage of Participants Receiving Darbepoetin Alfa With Improvement in Patient Perceived Fatigue (PPF) and Increase in Hemoglobin \u2265 1 g/dL",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosed with breast, colorectal, ovarian, prostate, lung, bladder, endometrial, renal, pancreatic, esophageal or gastric cancer\n* Expected to receive at least 8 additional weeks of a given regimen of myelosuppressive chemotherapy after enrolment\n* Starting treatment with either darbepoetin alfa (in Cohort 1 countries) or any ESA (in Cohort 2 countries) as per European Summary of Product Characteristics (SPC) for symptomatic anaemia.\n\nExclusion Criteria:\n\n* Received any ESA treatment or Red Blood Cell (RBC) transfusion within 28 days prior to enrolment\n* Known primary benign or malignant haematologic disorder which can cause anaemia\n* Known hypersensitivity to ESAs",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}